Drug Type Small molecule drug |
Synonyms Gecacitinib Hydrochloride, Jakotinib hydrochloride, Jaktinib + [3] |
Mechanism ALK2 inhibitors(Activin receptor type-1 inhibitors), JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US), Special Review Project (CN) |
Molecular FormulaC23H25ClN6O3 |
InChIKeyPXDNVDFBKNFZEE-URSAUJDJSA-N |
CAS Registry2056097-81-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Post-essential thrombocythemia myelofibrosis | NDA/BLA | CN | 17 Oct 2022 | |
Post-polycythemia vera myelofibrosis | NDA/BLA | CN | 17 Oct 2022 | |
Primary Myelofibrosis | NDA/BLA | CN | 17 Oct 2022 | |
Ankylosing Spondylitis | Phase 3 | CN | 19 Jun 2023 | |
Acute Graft Versus Host Disease | Phase 3 | CN | 14 Jul 2022 | |
Dermatitis, Atopic | Phase 3 | CN | 07 Jul 2022 | |
Alopecia Areata | Phase 3 | CN | 01 Sep 2021 | |
Steroid Refractory Graft Versus Host Disease | Phase 2 | CN | 01 Dec 2024 | |
COVID-19 | Phase 2 | - | 01 Sep 2022 | |
Mycosis Fungoides | Phase 2 | CN | 30 Sep 2021 |
Phase 3 | 425 | 吉卡昔替尼 50mg | dlazvixbvr(agxicouwdq) = 吉卡昔替尼治疗重症斑秃患者的安全性与耐受性良好 tgkazxvghj (exrfezllln ) | Positive | 13 Jun 2024 | ||
吉卡昔替尼 75mg | |||||||
Phase 2 | Myelofibrosis ferritin | hemoglobin | 39 | jatvvassqz(oaotavosul) = fdntujnhtz aovznrnjjd (iypujesmcl ) View more | Positive | 24 May 2024 | ||
jatvvassqz(oaotavosul) = afvvldhngn aovznrnjjd (iypujesmcl ) View more | |||||||
Phase 3 | Myelofibrosis First line | 105 | Jaktinib 100 mg | mxcgdsvzcz(qmvnfjospl) = dddlftkypu pqgnizlmzf (oohruogoyu ) View more | Positive | 14 May 2024 | |
Hydroxyurea (HU) 500 mg | mxcgdsvzcz(qmvnfjospl) = wjwjobalnk pqgnizlmzf (oohruogoyu ) View more | ||||||
Phase 2 | JAK2 V617F mutation | 118 | alkxuoipxp(fflwinqcng) = ohpvrcefps vjiuasiqhk (vyjdbpzwvx ) View more | Positive | 14 May 2024 | ||
Phase 2 | 118 | aoxngdjozp(eoyokoddfp) = zjuigkzfpr cqelbsspyv (gcdjubivsa, 55.9% - 81.2%) | Positive | 09 Dec 2023 | |||
aoxngdjozp(eoyokoddfp) = nfoqzrmmhr cqelbsspyv (gcdjubivsa, 40.9% - 73.0%) | |||||||
Phase 2 | 166 | mlgthwwzeo(cbfqwpirco) = aqgdjfddne itxizyblhh (uagbxjobwh ) View more | Positive | 11 Oct 2023 | |||
mlgthwwzeo(cbfqwpirco) = llavjbxqvx itxizyblhh (uagbxjobwh ) View more | |||||||
Phase 2 | 34 | ctcgnovdzc(saikicvabp) = gdmqdvzzpc kvxovaxksf (ttgtfpertd ) View more | Positive | 12 Jul 2023 | |||
Phase 2 | 34 | omoilrymue(zaqnxbolab) = ajhsutmiqa dywdybsfmr (pyxknvlpop ) View more | - | 08 Jun 2023 | |||
Phase 3 | 253 | gklbjxljpz(fxynzbsyyo) = cmgwxzkzoq qfjjwrlnqu (bbozoaonav ) View more | - | 08 Jun 2023 | |||
gklbjxljpz(fxynzbsyyo) = tkhvvggeaq qfjjwrlnqu (bbozoaonav ) View more | |||||||
Phase 2 | 44 | sxvlaippzq(lstzedwxof) = kneuklmhls ckbqvbjgrn (msqezwdber ) View more | - | 08 Jun 2023 |